ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target.
ATPase family AAA domain-containing protein 2 (ATAD2)
Anticancer drug
Cancer therapy
Epigenetic modification
Small-molecule inhibitor
Therapeutic target
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
09
2022
accepted:
22
12
2022
entrez:
12
1
2023
pubmed:
13
1
2023
medline:
14
1
2023
Statut:
epublish
Résumé
ATPase family AAA domain-containing protein 2 (ATAD2) has been widely reported to be a new emerging oncogene that is closely associated with epigenetic modifications in human cancers. As a coactivator of transcription factors, ATAD2 can participate in epigenetic modifications and regulate the expression of downstream oncogenes or tumor suppressors, which may be supported by the enhancer of zeste homologue 2. Moreover, the dominant structure (AAA + ATPase and bromine domains) can make ATAD2 a potential therapeutic target in cancer, and some relevant small-molecule inhibitors, such as GSK8814 and AZ13824374, have also been discovered. Thus, in this review, we focus on summarizing the structural features and biological functions of ATAD2 from an epigenetic modulator to a cancer therapeutic target, and further discuss the existing small-molecule inhibitors targeting ATAD2 to improve potential cancer therapy. Together, these inspiring findings would shed new light on ATAD2 as a promising druggable target in cancer and provide a clue on the development of candidate anticancer drugs.
Identifiants
pubmed: 36632213
doi: 10.7150/thno.78840
pii: thnov13p0787
pmc: PMC9830439
doi:
Substances chimiques
ATAD2 protein, human
EC 3.6.1.3
ATPases Associated with Diverse Cellular Activities
EC 3.6.4.-
DNA-Binding Proteins
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
787-809Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Medicine (Baltimore). 2019 Sep;98(39):e17180
pubmed: 31574824
J Enzyme Inhib Med Chem. 2020 Dec;35(1):713-725
pubmed: 32174193
Cell Death Dis. 2018 Mar 7;9(3):380
pubmed: 29515109
Exp Cell Res. 2020 Nov 1;396(1):112241
pubmed: 32835657
Mol Cell Biol. 2010 Nov;30(22):5260-72
pubmed: 20855524
J Biol Chem. 2021 Oct;297(4):101239
pubmed: 34563541
ACS Med Chem Lett. 2020 Jun 30;11(8):1573-1580
pubmed: 32832026
Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18067-72
pubmed: 17998543
iScience. 2022 Oct 31;25(12):105464
pubmed: 36404917
Onco Targets Ther. 2020 Jun 02;13:4931-4942
pubmed: 32581554
Oncol Lett. 2019 Feb;17(2):2400-2408
pubmed: 30719113
Oncotarget. 2015 Sep 29;6(29):28440-52
pubmed: 26308378
J Hematol Oncol. 2022 Feb 5;15(1):14
pubmed: 35123522
J Exp Clin Cancer Res. 2021 Mar 23;40(1):109
pubmed: 33757572
Eur J Med Chem. 2020 Nov 1;205:112648
pubmed: 32791401
Open Med (Wars). 2021 Jun 24;16(1):931-943
pubmed: 34222668
Mol Cells. 2014 Dec 31;37(12):851-6
pubmed: 25377252
Biochim Biophys Acta. 2013 Oct;1829(10):1010-4
pubmed: 23831842
Biol Chem. 2020 Feb 25;401(3):377-387
pubmed: 31721721
Oncotarget. 2015 Dec 8;6(39):41722-35
pubmed: 26497681
Oncogene. 2019 Jan;38(1):17-32
pubmed: 30072740
Oncotarget. 2017 May 23;8(21):34429-34441
pubmed: 28415780
Cancer Res Treat. 2015 Oct;47(4):853-61
pubmed: 25687855
J Med Chem. 2018 Sep 27;61(18):8321-8336
pubmed: 30226378
Nat Rev Drug Discov. 2020 Jul;19(7):480-494
pubmed: 32555376
Nat Rev Nephrol. 2016 Jun;12(6):325-38
pubmed: 27108839
Theranostics. 2021 Jan 1;11(4):1795-1813
pubmed: 33408782
Int J Mol Sci. 2021 Sep 21;22(18):
pubmed: 34576340
Cancer Res. 2009 Nov 1;69(21):8491-8
pubmed: 19843847
Endocr Relat Cancer. 2017 Nov;24(11):R403-R420
pubmed: 28924064
Biochem Biophys Res Commun. 2022 Feb 26;594:146-152
pubmed: 35085891
J Transl Med. 2022 May 13;20(1):212
pubmed: 35562734
Annu Rev Pathol. 2018 Jan 24;13:395-412
pubmed: 29414248
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
BMB Rep. 2019 Jul;52(7):457-462
pubmed: 31186081
J Med Chem. 2022 Feb 24;65(4):3306-3331
pubmed: 35133824
Expert Opin Ther Targets. 2018 Jan;22(1):85-96
pubmed: 29148850
Mol Cell Biol. 2004 Jun;24(12):5157-71
pubmed: 15169882
Cell Chem Biol. 2018 Apr 19;25(4):357-369.e6
pubmed: 29396292
Nat Rev Mol Cell Biol. 2017 Jul;18(7):407-422
pubmed: 28512350
Biomed Pharmacother. 2020 May;125:109964
pubmed: 32044716
J Hematol Oncol. 2020 Jul 28;13(1):104
pubmed: 32723346
J Med Chem. 2015 Jul 23;58(14):5649-73
pubmed: 26155854
Biochim Biophys Acta. 2015 May;1849(5):506-16
pubmed: 24704206
Neoplasma. 2016;63(6):873-879
pubmed: 27565325
J Exp Clin Cancer Res. 2017 Apr 27;36(1):60
pubmed: 28449718
Int J Oncol. 2020 Jan;56(1):219-231
pubmed: 31746426
Cell Signal. 2022 Sep 14;100:110469
pubmed: 36115547
Curr Opin Struct Biol. 2021 Feb;66:119-128
pubmed: 33246198
Endocr Rev. 2021 May 25;42(3):354-373
pubmed: 33480983
J Cell Physiol. 2019 Aug;234(10):19059-19072
pubmed: 30993715
Cancer Res. 2009 Apr 15;69(8):3339-46
pubmed: 19318566
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
Clin Cancer Res. 2010 Feb 15;16(4):1094-9
pubmed: 20145169
Life Sci. 2021 Jul 1;276:119322
pubmed: 33711386
Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):9860-9868
pubmed: 33090389
Proteins. 2019 Feb;87(2):157-167
pubmed: 30520161
Nat Commun. 2021 Jun 9;12(1):3483
pubmed: 34108481
Oncol Rep. 2020 Jan;43(1):318-327
pubmed: 31789405
Circulation. 2002 Jun 4;105(22):2653-9
pubmed: 12045172
Oncol Lett. 2021 Feb;21(2):166
pubmed: 33552284
Proc Natl Acad Sci U S A. 1988 Oct;85(19):7399-403
pubmed: 3174642
Biochem Biophys Res Commun. 2022 Dec 20;635:179-186
pubmed: 36279679
Cancer Manag Res. 2020 Jan 15;12:337-351
pubmed: 32021447
J Med Chem. 2011 Jun 9;54(11):3827-38
pubmed: 21568322
Oncol Lett. 2019 Mar;17(3):3489-3494
pubmed: 30867788
Cancer Cell. 2022 Jul 11;40(7):768-786.e7
pubmed: 35750052
Br J Pharmacol. 2020 Jul;177(13):2959-2973
pubmed: 32060899
J Mol Cell Biol. 2016 Aug;8(4):349-62
pubmed: 26459632
J Med Chem. 2012 Sep 13;55(17):7346-59
pubmed: 22788793
Angew Chem Int Ed Engl. 2016 Sep 12;55(38):11382-6
pubmed: 27530368
ACS Chem Biol. 2017 Nov 17;12(11):2730-2736
pubmed: 29043777
Prostate. 2013 Apr;73(5):455-66
pubmed: 23038103
Theranostics. 2020 Aug 1;10(21):9741-9766
pubmed: 32863957
Theranostics. 2020 Jul 29;10(21):9620-9643
pubmed: 32863950
Cell Mol Biol Lett. 2022 Jun 7;27(1):44
pubmed: 35672694
Eur Rev Med Pharmacol Sci. 2020 Jun;24(11):6055-6063
pubmed: 32572920
Cell Rep. 2017 Jun 6;19(10):2045-2059
pubmed: 28591577
Mol Cell Biol. 2012 Aug;32(15):3121-31
pubmed: 22645312
Mol Cancer Res. 2010 Feb;8(2):183-93
pubmed: 20124470
Oncotarget. 2016 Oct 25;7(43):70323-70335
pubmed: 27612420
Biomed Res Int. 2020 May 5;2020:8657468
pubmed: 32462022
Mol Endocrinol. 2012 Sep;26(9):1531-41
pubmed: 22771493
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
BMC Cancer. 2014 Feb 19;14:107
pubmed: 24552534
Cell Death Dis. 2018 Sep 27;9(10):1012
pubmed: 30262881
J Med Chem. 2015 Aug 13;58(15):6151-78
pubmed: 26230603
Science. 2021 Sep 03;373(6559):eabc1048
pubmed: 34516843
Life Sci. 2022 Jul 15;301:120592
pubmed: 35504332
Biochem J. 2015 Mar 1;466(2):337-46
pubmed: 25486442
J Med Chem. 2020 May 28;63(10):5212-5241
pubmed: 32321240
Mol Cancer Res. 2014 Apr;12(4):539-49
pubmed: 24391143
Annu Rev Biochem. 2022 Jun 21;91:183-195
pubmed: 35303789
Nat Commun. 2020 Jul 30;11(1):3806
pubmed: 32732922
Biochem Biophys Res Commun. 2020 Mar 19;523(4):916-923
pubmed: 31959473
Cancer Res. 2010 Nov 15;70(22):9402-12
pubmed: 20864510
Exp Ther Med. 2020 Mar;19(3):1997-2007
pubmed: 32104259
Bosn J Basic Med Sci. 2018 Feb 20;18(1):8-20
pubmed: 29274272
Mol Cell Biol. 2020 Apr 13;40(9):
pubmed: 32015101
Phys Chem Chem Phys. 2018 Sep 19;20(36):23222-23232
pubmed: 30137066
Oncogene. 2010 Sep 16;29(37):5171-81
pubmed: 20581866
Trends Biochem Sci. 2016 Jan;41(1):94-105
pubmed: 26678005
Int J Oncol. 2014 Jul;45(1):351-61
pubmed: 24805933
Cell Rep. 2022 Jun 14;39(11):110970
pubmed: 35705032
Cancer Gene Ther. 2023 Jan;30(1):192-208
pubmed: 36151333
Int J Med Sci. 2020 Jun 27;17(11):1598-1609
pubmed: 32669963
Nat Chem Biol. 2013 Sep;9(9):548-56
pubmed: 23892893
Cell. 2012 Mar 30;149(1):214-31
pubmed: 22464331
Nat Med. 2021 Jan;27(1):34-44
pubmed: 33442008
J Med Chem. 2019 Aug 22;62(16):7506-7525
pubmed: 31398032
Arch Med Res. 2016 Feb;47(2):89-95
pubmed: 27131099
Cell. 2008 Feb 8;132(3):344-62
pubmed: 18267068
J Med Chem. 2014 Nov 26;57(22):9687-92
pubmed: 25314628
J Cell Physiol. 2018 Mar;233(3):1877-1886
pubmed: 28500727
Clin Cancer Res. 2013 Jan 15;19(2):450-61
pubmed: 23209032
Int J Mol Sci. 2021 Aug 24;22(17):
pubmed: 34502039
J Clin Oncol. 2003 Jul 1;21(13):2537-44
pubmed: 12829673